| Vasculitis |
1 |
1 |
| Antiviral Agents |
0 |
0.42 |
| Hospital |
0 |
0.42 |
| Patient Safety |
0 |
0.36 |
| Influenza |
0 |
0.3 |
| Congenital Anomaly |
0 |
0.29 |
| Drug Reaction |
0 |
0.29 |
| Interstitial Lung Disease |
0 |
0.29 |
| Tyrosine Kinase Inhibitor |
0 |
0.29 |
| Biologic Therapy |
0 |
0.22 |
| Antihypertensive Agents |
0 |
0.21 |
| Arthritis |
0 |
0.21 |
| Birth |
0 |
0.21 |
| Bladder |
0 |
0.21 |
| Disability |
0 |
0.21 |
| Drug and Treatment Safety |
0 |
0.21 |
| Id Reaction |
0 |
0.21 |
| Influenza Vaccine |
0 |
0.21 |
| Lung |
0 |
0.21 |
| Prognosis |
0 |
0.21 |
| Tyrosine Kinase |
0 |
0.21 |
| Antibiotics |
0 |
0.14 |
| Asthma |
0 |
0.14 |
| Dermatitis |
0 |
0.14 |
| Gout |
0 |
0.14 |
| Hypertension |
0 |
0.14 |
| Tuberculosis |
0 |
0.14 |
| Vaccines |
0 |
0.14 |